Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16268183 | 0.96 | HIF1A (0.44) | HIF1ASNCAAKR1B1SMN1; SMN2TAAR1 | |
| Hydrochloric Acid SCHEMBL2533980 | 0.83 | HIF1A (0.38) | HIF1ASNCAAKR1B1SMN1; SMN2TAAR1 | |
| Bromide SCHEMBL5827732 | 0.83 | DPP4 (0.41) | SNCASMN1; SMN2DPP4TDP1LMNA | |
| Hydrochloric Acid SCHEMBL6366549 | 0.79 | DPP4 (0.41) | SMN1; SMN2SLC6A2SLC6A4SLC6A3DPP4 | |
| Bromide SCHEMBL5829267 | 0.79 | IDO1 (0.45) | HIF1ASNCATAAR1SLC6A2SLC6A4 | |
| Bromide SCHEMBL5829428 | 0.77 | CHRNA7 (0.39) | HIF1ASNCASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31412768 | 0.77 | IDO1 (0.46) | HIF1ASNCATAAR1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL2720227 | 0.75 | IDO1 (0.45) | HIF1ASNCATAAR1SLC6A2SLC6A4 | |
| Bromide SCHEMBL4178635 | 0.75 | HIF1A (0.44) | HIF1ASNCATAAR1SLC6A2SLC6A4 | |
| Bromide SCHEMBL71991 | 0.75 | HIF1A (0.44) | HIF1ASNCASMN1; SMN2TAAR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-9421210-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2016-07-07 | — | — | US | disclosed |
| US-9314467-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9273017-B2 | (Thio)morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LIMITED (BS) | 2016-03-01 | — | — | US | disclosed |
| CN-102548976-B | (thio) morpholine derivatives as S1P modulators | ABBVIE BAHAMAS LTD. (BS) | 2015-09-09 | — | — | CN | disclosed |
| US-20150239857-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | ABBVIE BAHAMAS LIMITED (BS) | 2015-08-27 | — | — | US | disclosed |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150166495-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166494-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. | 2015-06-18 | — | — | US | disclosed |
| US-5698711-A | INHIBITORS OF TUMOR NECROSIS FACTOR, CYCLIC ADENOSINE-3*,5*-MONOPHOSPHATE PHOSPHODIESTERASE AND EOSINOPHILS | RHONE-POULENC RORER LIMITED (GB) | 1997-12-16 | — | — | US | disclosed |
| US-5679696-A | FOR INHIBITING TUMOR NECROSIS FACTOR; ENZYME INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1997-10-21 | — | — | US | disclosed |
| EP-0757682-A1 | BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| EP-0711282-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995029907-A1 | BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-09 | — | — | WO | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
| EP-0652868-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1995004045-A1 | COMPOUNDS AS PDE IV AND TNF INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-02-09 | — | — | WO | disclosed |
| WO-1994002465-A1 | INHIBITORS OF c-AMP PHOSPHODIESTERASE AND TNF | RHONE-POULENC RORER LIMITED (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239857-A1 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS | S1PR3, S1PR1, S1PR2 | HIF1A 1855/4885SNCA 1575/4885AKR1B1 2871/4885 |
| US-20150166495-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | HIF1A 2004/4885SNCA 65/4885AKR1B1 733/4885 |
| US-20150166494-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | HIF1A 2004/4885SNCA 65/4885AKR1B1 733/4885 |
| US-20150238497-A1 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, STARD3, TXNRD2 | HIF1A 2004/4885SNCA 65/4885AKR1B1 733/4885 |
| US-20160193160-A1 | Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ALDH1A2, STARD3, TXNRD2 | HIF1A 2004/4885SNCA 65/4885AKR1B1 733/4885 |
| US-10201545-B2 | Styrenyl derivative compounds for treating ophthalmic diseases and disorders | ALDH1A2, STARD3, TXNRD2 | HIF1A 2004/4885SNCA 65/4885AKR1B1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.